4.6 Article

Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled Trial

Journal

JOURNAL OF BONE AND MINERAL RESEARCH
Volume 37, Issue 11, Pages 2165-2173

Publisher

WILEY
DOI: 10.1002/jbmr.4703

Keywords

BIOCHEMICAL MARKERS OF BONE TURNOVER; GENERAL POPULATION STUDIES; NUTRITION

Funding

  1. Danish Cancer Society
  2. Research Foundation of the County of Funen
  3. Cypress Systems Inc.
  4. Danish Veterinary and Food Administration
  5. Council of Consultant Physicians, Odense University Hospital
  6. Clinical Experimental Research Foundation at Department of Oncology, Odense University Hospital
  7. K.A Rohde's Foundation
  8. Dagmar Marshall's Foundation
  9. MRC-Versus Arthritis Centre for Integrated Research into Musculoskeletal Aging (CIMA)
  10. Cumbria Community Foundation
  11. Beverley Charitable Trust

Ask authors/readers for more resources

The effects of long-term selenium supplementation on bone turnover markers were investigated. The study found no significant impact of selenium supplementation on these markers. The relatively high baseline selenium status of the participants may explain this lack of effect.
Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long-term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N-terminal propeptide (PINP), collagen type I cross-linked C-telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60-74 years) were randomized to receive placebo-yeast versus 100, 200, or 300 mu g selenium as selenium-enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose-response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 mu g/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 mu g/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 mu g/L for 100, 200, and 300 mu g supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo-treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available